Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

NCT04657094 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Warm Antibody Autoimmune Hemolytic Anemia

Interventions

DRUG: Acalabrutinib

Sponsor

City of Hope Medical Center

Collaborators

[object Object]